MBX Biosciences, Inc.
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 76.64% | 62.51% | 80.42% | 82.08% | 45.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.61% | 22.00% | 30.90% | 99.26% | 86.27% |
| Operating Income | -38.61% | -22.00% | -30.90% | -99.26% | -86.27% |
| Income Before Tax | -41.55% | -19.16% | -22.41% | -93.56% | -76.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.55% | -19.16% | -22.41% | -93.56% | -76.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.55% | -19.16% | -22.41% | -93.56% | -76.25% |
| EBIT | -38.61% | -22.00% | -30.90% | -99.26% | -86.27% |
| EBITDA | -38.72% | -22.21% | -31.03% | -99.40% | -86.45% |
| EPS Basic | -5.14% | 77.30% | 95.40% | 93.03% | 93.96% |
| Normalized Basic EPS | -3.00% | 77.30% | 95.40% | 93.03% | 93.58% |
| EPS Diluted | -5.01% | 77.30% | 95.40% | 93.03% | 93.95% |
| Normalized Diluted EPS | -3.00% | 77.30% | 95.40% | 93.03% | 93.58% |
| Average Basic Shares Outstanding | 34.64% | 424.87% | 2,561.87% | 2,678.81% | 2,817.40% |
| Average Diluted Shares Outstanding | 34.64% | 424.87% | 2,561.87% | 2,678.81% | 2,817.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |